Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 4,307 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Liver Disease Clear all
Completed Not applicable Interventional Results available

Endoscopic Ultrasound(EUS)-Guided TRUCUT Biopsy (EUS-TCB) of Suspected Nonalcoholic Fatty Liver Disease(NAFLD.)

NCT00586313
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Interventions
Tru-cut biopsy, Tru-cut
Device · Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Phase 1 Interventional

Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer

NCT02292173
View directory record Official record
Conditions
Hepatocellular Cancer, Liver Cancer
Interventions
Trametinib, Sorafenib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C

NCT00262483
View directory record Official record
Conditions
Hepatitis C
Interventions
VX-950, ribavirin, peginterferon alfa-2a
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2007 · Synced Oct 20, 2026, 10:14 PM EDT
Active, not recruiting Phase 1 Interventional

Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)

NCT02932956
View directory record Official record
Conditions
Liver Cancer
Interventions
GAP T cells, Cytoxan, Fludara
Genetic · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2037
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 20, 2026, 10:14 PM EDT
Completed No phase listed Observational

Digital Pathology and AI for Liver Outcomes in MASLD (DPAILO-2)

NCT06493253
View directory record Official record
Conditions
Metabolic Dysfunction-associated Steatotic Liver Disease
Interventions
Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)
Diagnostic Test
Lead sponsor
PharmaNest, Inc
Industry
Eligibility
18 Years to 90 Years
Enrollment
1,519 participants
Timeline
2025 – 2026
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Not applicable Interventional

The Referral to Hepatology Can be Improved Through an Electronic Medical Record (EMR)-Based Best Practice Alert (BPA) for an Appropriate Referral

NCT07580482
View directory record Official record
Conditions
Liver Diseases, Liver Fat, Diabetes Mellitus, Type 2, Non-Alcoholic Steatohepatitis
Interventions
Best Practice Alert, No Intervention
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Cherries Role in Gut Microbiota-liver-brain Function

NCT05586386
View directory record Official record
Conditions
Obesity
Interventions
Cherry group, Placebo group
Other
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Oct 20, 2026, 10:14 PM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry

NCT07732686
View directory record Official record
Conditions
Pancreas Cancer, Hepatocellular Carcinoma, Lung Cancer, Ovarian Cancer, Breast Cancer, Head and Neck Cancer, Colon Cancer, Bladder Cancer, Other Cancer
Interventions
Proton Transfer Reaction Mass Spectrometry Analysis
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Phase 2 Interventional

Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis

NCT05011305
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Fibrosis
Interventions
Saroglitazar Magnesium 2 mg, Saroglitazar Magnesium 4 mg, Placebo
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
101
States / cities
Birmingham, Alabama • Homewood, Alabama • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Phase 1 Interventional

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00020579
View directory record Official record
Conditions
Cancer
Interventions
entinostat
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 20, 2026, 10:14 PM EDT
Withdrawn Phase 1Phase 2 Interventional

A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma

NCT06006286
View directory record Official record
Conditions
Metastatic Hepatocellular Carcinoma
Interventions
Atezolizumab, Bevacizumab, ADI-PEG 20
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

The University of Michigan Wellness for Liver Health Study

NCT05010070
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
diet and lifestyle program
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 20, 2026, 10:14 PM EDT
Recruiting No phase listed Observational

Evaluating Alcohol Use in Alcoholic Liver Disease

NCT03267069
View directory record Official record
Conditions
Alcoholic Liver Disease
Interventions
survey
Other
Lead sponsor
Nicole T Shen
Other
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 20, 2026, 10:14 PM EDT
Recruiting Not applicable Interventional

Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH

NCT03845205
View directory record Official record
Conditions
Alcohol Use Disorder, Alcoholic Hepatitis
Interventions
Integrated AUD Treatment
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 20, 2026, 10:14 PM EDT
Withdrawn Phase 4 Interventional

Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases

NCT00510627
View directory record Official record
Conditions
Metastatic Liver Cancer, Secondary Liver Cancer, Liver Neoplasm
Interventions
Radiofrequency Ablation (RFA), Chemotherapy
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 20, 2026, 10:14 PM EDT
Completed No phase listed Observational

Social-environmental, Psychosocial, Behavioral, Clinical and Biological Drivers of Disparities in Liver Disease Progression Among Korean American With Chronic Hepatitis B Infection

NCT05117541
View directory record Official record
Conditions
Chronic Viral Hepatitis, Hepatitis B Infection
Interventions
Interview, Biospecimen Collection, Electronic Health Record Review
Other · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
365 participants
Timeline
2021 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 20, 2026, 10:14 PM EDT
Recruiting No phase listed Observational

Multi-analyte Blood Test Clinical Trial

NCT05199259
View directory record Official record
Conditions
Liver Cirrhosis, Liver Cancer, HCC, Hepatocellular Carcinoma
Interventions
Multi-analyte Blood Test
Diagnostic Test
Lead sponsor
Helio Genomics
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Timeline
2022 – 2028
U.S. locations
7
States / cities
Escondido, California • Mission Hills, California • Gainesville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 20, 2026, 10:14 PM EDT
Completed No phase listed Observational

Direct Acting Antiviral-Post Authorization Safety Study

NCT03707080
View directory record Official record
Conditions
Hepatitis C, Hepatocellular Carcinoma
Interventions
Not listed
Lead sponsor
Target PharmaSolutions, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
47
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Phase 2 Interventional

Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis

NCT02686762
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Fibrosis, Liver Diseases
Interventions
Emricasan (5 mg), Emricasan (50 mg), Placebo
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
83
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 20, 2026, 10:14 PM EDT
Recruiting No phase listed Observational

Colorectal Metastasis to Liver Extraction With Auxiliary Transplant and Delayed Resection

NCT06698146
View directory record Official record
Conditions
Liver Transplant Surgery, Colorectal Cancer Metastatic, Colon Cancer Liver Metastases
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 20, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY2157299 in Participants With Hepatocellular Carcinoma

NCT01246986
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
LY2157299, Sorafenib, Ramucirumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
10
States / cities
Fayetteville, Arkansas • San Francisco, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 20, 2026, 10:14 PM EDT
Completed No phase listed Observational

Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition

NCT05011370
View directory record Official record
Conditions
Intestinal Failure-associated Liver Disease
Interventions
Not listed
Lead sponsor
Protara Therapeutics
Industry
Eligibility
12 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Los Angeles, California • Kissimmee, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 20, 2026, 10:14 PM EDT
Completed No phase listed Observational

Measurement of Pro-angiogenic Markers in Patients With Hepatic Metastases Undergoing SIRT

NCT00994370
View directory record Official record
Conditions
Liver Cancer
Interventions
Not listed
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 20, 2014 · Synced Oct 20, 2026, 10:14 PM EDT
Completed No phase listed Observational

Genomic Research in Alpha-1 Antitrypsin Deficiency

NCT01832220
View directory record Official record
Conditions
Alpha 1 Antitrypsin Deficiency, AATD
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
40 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
9
States / cities
Tucson, Arizona • San Francisco, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Oct 20, 2026, 10:14 PM EDT